Supplements And Featured Publications
New Insights Into ADHD
Clinical Utility of GEMTESA® (vibegron) in Diverse Managed OAB Populations
Sponsored by Sumitomo Pharma America, Inc.
New Insights Into Hypophosphatasia
The Broader Impact of GEMTESA® (vibegron) in Addressing OAB in Men Receiving BPH Therapy
Sponsored by Sumitomo Pharma America, Inc.
Clinical and Economic Impact of OAB Symptoms in Men Receiving Pharmacological Treatment for BPH
Sponsored by Sumitomo Pharma America, Inc.
Vaccination in Cancer Care
Nonfactor Therapies for Hemophilia
Advancing Myelofibrosis Care: Balancing Clinical Innovation With Economic Impact
The future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
Sponsored by Dexcom, Inc.
The Evolving Landscape of Pediatric Atopic Dermatitis Management
Pulmonary arterial hypertension: Advances and implications for managed care
Conference Brief: Asembia’s AXS25 Summit: A Special Report on Specialty Pharmacy
Advancing Hyperlipidemia Management: Nonstatin Therapies in Guideline-Based Care
Sponsored by Esperion.
The lingering threat of COVID-19 Confronting its burden in 2025
Supporting Families Optimizing Employee Fertility Benefits
Atopic Dermatitis in the Modern Era Assessing Patient Outcomes and Economic Burden
Advances in the Treatment of IgA Nephropathy
Update on RNA-Based Technology
Sponsored by Alnylam Pharmaceuticals, Inc.
Progress in Addressing Hyperlipidemia in the Primary Prevention Setting
Synergie Medication Collective Innovating for Medication Cost Savings
Demodex blepharitis: Navigating Diagnosis and Management Challenges
Understanding the Average Sales Price Landscape
Volume: 33
Issue: 10
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CagriSema reduces HbA1c, weight across T2D spectrum in REIMAGINE trials | ADA 2026
2
Lee Kaplan, M.D., discusses the metabolic case for survodutide | ADA 2026
3
Nearly half of older adults with metastatic lung cancer never receive systemic therapy, study finds
4
Machine learning model predicts T2D risk up to 10 years before onset
5